Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Bentamapimod
CHF 0.00
In stock
SYN-1147-M0011 mgCHF 270.00
SYN-1147-M0055 mgCHF 454.00
SYN-1147-M01010 mgCHF 653.00
SYN-1147-M05050 mgINQ
SYN-1147-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | AS-602801 |
| Product Type | Chemical |
| Properties | |
| Formula | C25H23N5O2S |
| MW | 457.6 |
| CAS | 848344-36-5 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | XCPPIJCBCWUBNT-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Bentamapimod (AS602801) is a novel and orally active c-Jun-N-Terminal Kinase Inhibitor highly specific for JNK kinases. The inhibitor Bentamapimod (AS602801) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative abdominal adhesions. Pre-clinical data have demonstrated Bentamapimod to be an effective anti-inflammatory compound with anti-fibrotic properties. Bentamapimod (AS602801) showed good bioavailability in rats (F=50%). It does cross the blood brain barrier, with 98% brain penetration the drug has been well tolerated so far. Bentamapimod (AS602801) is a potent and selective JNK inhibitor with therapeutic potential in MS and fibrosis as well.
Product References
- Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD? I.M. Adcock & G. Caramori; BioDrugs 18, 167 (2004)
Related Products
